Form 4: Assertio Holdings Acquired by Zydus in $23.50 Cash Deal

Assertio Holdings, Inc. has been acquired by Zydus Worldwide DMCC in an all-cash transaction at $23.50 per share.

Summary

• Assertio Holdings, Inc. completed a merger with Zydus Worldwide DMCC on June 16, 2026.
• The transaction involved a tender offer for all outstanding common stock at $23.50 per share in cash.
• Paul Schwichtenberg, President and COO, disposed of his remaining 13,987 shares of common stock as part of the merger.
• All outstanding restricted stock units (RSUs) and stock options were cancelled and converted into cash payments based on the $23.50 offer price.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents the final administrative filing for a completed acquisition rather than new operational performance.

Positives

• Shareholders received a definitive cash exit at $23.50 per share.
• Unvested RSUs were accelerated and fully vested immediately prior to the merger completion.
• In-the-money stock options were cashed out based on the spread between the offer price and the exercise price.

Negatives

• Stock options with an exercise price equal to or greater than the $23.50 offer price were cancelled without any cash payment.
• The company ceases to be an independent publicly traded entity.

Risks

• The company is now a wholly owned subsidiary of Zydus, eliminating public market exposure for investors.

Future Outlook

The company has been acquired and is now a wholly owned subsidiary of Zydus Worldwide DMCC; no further independent public guidance is provided.

Management Comments

• The filing confirms the completion of the merger and the conversion of all equity interests into cash rights.

Industry Context

StockSavvy.ai notes that this acquisition represents a consolidation in the pharmaceutical sector, with Zydus expanding its portfolio through the acquisition of Assertio's assets.

Comparison to Industry Standards

• The all-cash tender offer structure is a standard mechanism for pharmaceutical M&A transactions.
• The acceleration of unvested equity awards is consistent with typical change-in-control provisions in executive compensation agreements.

Corporate Governance

Stakeholder Impact

• Shareholders received cash proceeds for their holdings.
• Employees and management are now under the control of Zydus Worldwide DMCC.

Next Steps

• Delisting of Assertio Holdings (ASRT) from public exchanges.

Key Dates

Keywords

Assertio Holdings, ASRT, Merger, Acquisition, Zydus, Tender Offer, SEC Form 4